Find a Tender
planned
Official procurement procedure
HLA Sequencing Systems
Diagnostic kits
Medical consumables
Medical equipments
+1 more
UK
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS Blood and Transplant: "HLA Sequencing Systems". Published status: planned. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | NHS Blood and Transplant | Scope & Categories | Not published | Submission Window | planned No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: NHS Blood and Transplant
Market Analytics
Derived from OCDS awards & bid statistics
Published history for NHS Blood and Transplant. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Competition Density
Not availableNo published reports
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 0 active published awards; 0 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityNHS Blood and Transplant | Procedure methodNot published | Procurement categoryNot published |
Statusplanned | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published6 May 2021, 14:19 BST | Last source update6 May 2021, 14:19 BST | Recurring procurementNot published |
ClassificationDiagnostic kits, Medical consumables, Medical equipments, Repair and maintenance services of medical equipment | ||
Delivery area UK | ||
OCIDocds-h6vhtk-02aded | ||
What is being bought
Please see section II.2.4 for details. Prior to commencing a formal procurement process and to help inform our strategy, NHSBT is seeking to engage with suppliers of commercially available HLA sequencing systems. Our current contract ends in June 2022 and NHSBT would like to improve our knowledge of all current and future systems available in the marketplace. This will aid identification of opportunities and gauge market interest in this field.
What changed
From the official release history
- Status changed to planned
6 May 2021, 14:19 BST - Official notice release published
6 May 2021, 14:19 BST - Buyer information updated
6 May 2021, 14:19 BST
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedplannedPublished valueNot publishedNHS Blood & Transplant (NHSBT) Histocompatibility & Immunogenetics function intends to undertake an OJEU tender exercise for the supply of HLA sequencing systems.Histocompatibility & Immunogenetics (H&I) is a strategic business function of NHSBT, providing testing and support in transplantation, specialised transfusion including the supply of selected blood products, immunogenetics, platelet and granulocyte immunology. Services are supplied through a national network of six laboratories across England. Building on our strengths as a national provider, NHSBT’s strategic aim is for its diagnostic services to become the preferred provider and supplier of choice for these services in the NHS in England. We would like to work with future suppliers to realise this ambition and to perform HLA typing in an efficient, timely and cost-effective manner to meet the demands and expectations of our customers and the patients we serve.Prior to commencing a formal procurement process and to help inform our strategy, NHSBT is seeking to engage with suppliers of commercially available HLA sequencing systems. Our current contract ends in July 2022 and NHSBT would like to improve our knowledge of all current and future systems available in the marketplace. This will aid identification of opportunities and gauge market interest in this field. We require HLA typing systems to cover the following:• Allelic Test Kits SHOULD detect and uniquely identify all alleles of the HLA-A, B, C, DRB1, DRB3/4/5, DQA1, DQB1, DPA1 and DPB1 loci at the level of resolution that additionally defines the third field according to WHO nomenclature by at least resolving all ambiguities resulting from: (1) polymorphisms located within the exons coding for HLA class I and class II proteins and (2) that encompass a null allele wherever the polymorphism is located.• The optimal solution SHOULD define fourth field level resolution• Provision of maintenance, reagents and consumables for our existing instruments (Miseq (Illumina) pre-April 2021).NB: Procurement of the above systems may be managed by individual tenders.It is NHSBT's intention to hold pre-procurement engagement meetings the week of 7th to 11th June 2021, these will be held remotely, the date to be confirmed. To enable NHSBT to finalise arrangements (e.g. send meeting details and agree time slots) for the supplier engagement meetings, interested organisations are required to send an expression of interest via email to marta.drozdzowska@nhsbt.nhs.uk by no later than 17:00 hrs (GMT) on 28/05/21. This should include a list of your potential attendees and a brief overview (or a website link) of the Goods / Services which might be offered. Please include options, if available, to offer a managed service contract.No business whatsoever is guaranteed under any resulting framework agreement or contract, indeed there is no guarantee that any framework agreement or contract will be put in place in relation to this notice. No compensation etc. will be paid if a tender or resulting framework agreement is withdrawn for any reason. Bidders should take part in this process only on the basis that they fully understand and accept this position.It should be noted that this procurement exercise may allow other Health authorities to utilise any contracts/ framework agreements awarded.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
6 May 2021, 14:19 BST
Commercial outcome and competition
AwardsNo award published |
ContractsNo contract published |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
NHS Blood and Transplant
Contracting authority GB-FTS-15374Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published